March 23, 2022
Eisai’s investigational Alzheimer’s drug lecanemab showed rapid amyloid clearance from the brain and delivered data to determine the most effective dose, according to the latest findings from a PIIb trial, dubbed Study 201, and its open-label extension program. Study 201...read more